Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > IL-7 R alpha & TSLP R > EP-129

TSLP [Biotinylated] : IL-7Rα & TSLP R Inhibitor Screening ELISA Kit

For research use only.

Order Now

    Materials Provided
    IDComponentsSize
    EP129-C01 High-bind Plate 1 plate
    EP129-C02Human IL-7 R alpha & TSLP R25 μg
    EP129-C03Anti- TSLP Neutralizing Antibody20 μg
    EP129-C04Human TSLP-Biotin10 μg
    EP129-C05Streptavidin-HRP10 μg
    EP129-C06Coating Buffer12 mL
    EP129-C0710xWashing Buffer 50 mL
    EP129-C08Blocking Buffer50 mL
    EP129-C09Substrate Solution12 mL
    EP129-C10Stop Solution7 mL
  • Background
    Thymic stromal lymphopoietin (TSLP) exerts its biological effects by binding to a high-affinity heteromeric complex composed of thymic stromal lymphopoietin receptor chain and IL-7Rα.The formation of the ternary complex, TSLPR:TSLP: IL-7Rα,initiates signaling in cells co-expressing TSLPR and IL-7Rα.TSLP has been implicated in a variety of allergic diseases (e.g., atopic dermatitis, bronchial asthma, eosinophilic esophagitis). Therefore, inhibition of TSLP interaction with TSLP receptor complex has been considered a promising strategy to blocks thymic stromal lymphopoietin (TSLP) function and prevents the overreactive immune response to allergic,eosinophilic and other types of airway inflammation associated with severe asthma.
  • Application

    This kit is developed for screening for inhibitors of TSLP binding to human IL-7Rα & TSLP R.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new TLSP pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human TLSP to immobilized human IL-7 R alpha & TSLP R in a functional ELISA assay, and employs a simple colorimetric sandwich ELISA platform.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human IL-7 R alpha & TSLP R.

    b) Add your molecule of interest to the tests.

    c) Add human TLSP-Biotin to bind the coated human IL-7 R alpha & TSLP R.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the ability of your compound to inhibit TSLP: IL-7 R alpha & TSLP Rbinding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to DS document for the assay protocol.
 IL-7 R alpha & TSLP R TYPICAL DATA

INHIBITION OF TSLP [BIOTINYLATED]: IL-7 R ALPHA & TSLP R BINDING BY ANTI-TSLP NEUTRALIZING ANTIBODY
Serial dilutions of Anti-TSLP Neutralizing antibody (Catalog # EP129-C03) (1:1 serial dilution, from 8 μg/mL to 0.0156 μg/mL (55.317-0.108 nM)) was added into IL-7 R alpha & TSLP R: TSLP-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

 IL-7 R alpha & TSLP R TYPICAL DATA

INHIBITION OF TSLP [BIOTINYLATED]: IL-7 R ALPHA & TSLP R BINDING BY ANTI- TSLP & IL-13 BISPECIFIC ANTIBODY
Serial dilutions of anti TSLP & IL-13 bispecific antibody (1:1 serial dilution, from 8 μg/mL to 0.0156 μg/mL (55.317-0.108 nM)) was added into IL-7 R alpha & TSLP R: TSLP-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (Routinely tested).

  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:9 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message